2 assets in Aggressive Systemic Mastocytosis

Therapeutic assets addressing Aggressive Systemic Mastocytosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Bezuclastinib Aggressive Systemic Mastocytosis	Cogent Biosciences, Inc.	P2	CCC (53)
mgd024 Aggressive Systemic Mastocytosis	MacroGenics	P1	NR ()